Patent Assignment
Reel/Frame 045759/0917
Intellectual Property Security Agreement
Recorded: 2018-03-28
Pages: 33
Assignor
MESOBLAST INTERNATIONAL SARL
Executed: 2018-03-26
Assignee
HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
400 HAMILTON AVENUE, SUITE 310, PALO ALTO, CALIFORNIA, 94301
Covered Properties
(54)
Ligands That Modulate Differentiation of Mesenchymal Stem Cells
Patent:
6,022,540 →
Application:
09/141,882 →
Antigen Presenting Cells of the Adipocyte Lineage
Patent:
6,149,906 →
Application:
09/157,008 →
Mesenchymal Stem Cells as Immunosuppressants
Mesenchymal Stem Cells for Prevention and Treatment of Immune Responses in Transplantation
Patent:
6,328,960 →
Application:
09/267,536 →
Uses for Non-Autologous Mesenchymal Stem Cells
Patent:
6,355,239 →
Application:
09/314,855 →
Human Mesenchymal Stem Cells
Patent:
6,387,367 →
Application:
09/321,924 →
Regulation of Hematopoietic Stem Cell Differentiation by the Use of Human Mesenchymal Stem Cells
Patent:
6,255,112 →
Application:
09/327,796 →
In Vitro Maintenance of Hematopoietic Stem Cells
Patent:
6,030,836 →
Application:
09/327,840 →
Suppressor Cells for Prevention and Treatment of Immune Responses in Transplantation
Mesenchymal Stem Cells for Prevention and Treatment of Immune Responses in Transplantation
Patent:
6,368,636 →
Application:
09/427,333 →
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Patent:
6,387,369 →
Application:
09/446,952 →
Ligands That Modulate Differentiation of Mesenchymal Stem Cells
Patent:
6,379,953 →
Application:
09/452,142 →
A Method of Preparing Suppressor T Cells with Allogeneic Mesenchymal Stem Cells
Patent:
6,281,012 →
Application:
09/563,768 →
Antigen Presenting Mesenchymal Stem Cells
Patent:
7,101,704 →
Application:
09/638,358 →
Production of Megakaryocytes by the Use of Human Mesenchymal Stem Cells
Uses for Non-Autologous Mesenchymal Stem Cells
Mesenchymal Stem Cells for Prevention and Treatment of Immune Responses in Transplantation
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Purified Mesenchymal Stem Cell Compositions and Methods of Purifying Mesenchymal Stem Cell Compositions
Cardiac Muscle Repair or Regeneration Using Bone Marrow-Derived Stem Cells
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Protease-Resistant Mutants of Stromal Cell Derived Factor-1 in the Repair of Tissue Damage
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
Cardiac Muscle Repair or Regeneration Using Bone Marrow-Derived Stem Cells
Cardiac Muscle Repair or Regeneration Using Bone Marrow-Derived Stem Cells
Cardiac Muscle Repair or Regeneration Using Bone Marrow-Derived Stem Cells
Mesenchymal Stem Cells Expressing TNF-alpha Receptors
Cardiac Muscle Repair or Regeneration Using Bone Marrow-Derived Stem Cells
Joint Repair Using Mesenchymal Stem Cells
Mesenchymal Stem Cells and Uses Therefor
Methods for Repairing Tissue Damage Using Protease-Resistant Mutants of Stromal Cell Derived Factor-1
Enhanced Msc Preparations
Mesenchymal Stem Cells and Uses Therefor
Mesenchymal Stem Cells and Uses Therefor
Method of Treating the Effects of Stroke
Application:
14/456,534 →
Publication:
US 2016/0361362
Enhanced Msc Preparations
Joint Repair Using Mesenchymal Stem Cells
Mesenchymal Stem Cells and Uses Therefor
Application:
14/739,924 →
Publication:
US 2015/0272997
Protease-Resistant Mutants of Stromal Cell Derived Factor-1 in the Repair of Tissue Damage
Methods for Repairing Tissue Damage Using Protease-Resistant Mutants of Stromal Cell Derived Factor-1
Application:
15/103,153 →
Publication:
US 2016/0303197
Production of Reprogrammed Pluripotent Cells
Application:
15/299,088 →
Publication:
US 2017/0037377
Improved Stem Cell Composition
Treatment of Immune Disorders
Method for Treating Heart Failure
Prevention of Progressive Heart Failure
Cell Culture Method for Mesenchymal Stem Cells
Application:
15/553,115 →
Publication:
US 2018/0037867
Potency Assay
Methods and Apparatus for Separating Cells from Microcarriers
Purified Mesenchymal Stem Cell Compositions and Methods of Purifying Mesenchymal Stem Cell Compositions
Application:
15/602,848 →
Publication:
US 2018/0008642
Mesenchymal Stem Cells Expressing Tnf-Alpha Receptors
Application:
15/693,754 →
Publication:
US 2018/0087032
Treatment of Excessive Neovascularization
Application:
15/788,438 →
Publication:
US 2018/0369286
Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof
Application:
15/847,009 →
Publication:
US 2018/0237746
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 1, 2013
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031533/0828 →
Assignment of Assignor's Interest
Mar 20, 2014
From: QASBA, PANKAJ
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 032488/0907 →
Assignment of Assignor's Interest
Mar 20, 2014
From: MOORMAN, MARK AARON; SIMONETTI, DONALD WILLIAM, JR; HAMMILL, LORA CATHERINE; CRAIG, STEWART
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 032489/0020 →
Corrective Assignment to Correct the Patent Number 7387367 Previously Recorded on Reel 032489 Frame 0020. Assignor(S) Hereby Confirms the Patent Number 6387367.
Apr 10, 2014
From: MOORMAN, MARK AARON; SIMONETTI, DONALD WILLIAM, JR; HAMMILL, LORA CATHERINE; CRAIG, STEWART
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 032664/0362 →
Intellectual Property Security Agreement
Jul 10, 2018
From: MESOBLAST INTERNATIONAL SARL
To: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 046515/0222 →
Security Interest
Feb 28, 2020
From: NUVASIVE, INC.; NUVASIVE CLINICAL SERVICES MONITORING, INC.; NUVASIVE CLINICAL SERVICES, INC.; NUVASIVE SPECIALIZED ORTHOPEDICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 052918/0595 →
Security Interest
Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
Release of Intellectual Property Security Agreement at Reel/Frame No. 45759/0917
Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
Release of Security Interest in Intellectual Property
Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →